GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » Price-to-Owner-Earnings

Getein Biotech (SHSE:603387) Price-to-Owner-Earnings : 44.80 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech Price-to-Owner-Earnings?

As of today (2024-05-27), Getein Biotech's share price is ¥8.96. Getein Biotech's Owner Earnings per Share (TTM) ended in Mar. 2024 was ¥0.20. It's Price-to-Owner-Earnings for today is 44.80.


The historical rank and industry rank for Getein Biotech's Price-to-Owner-Earnings or its related term are showing as below:

SHSE:603387' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.21   Med: 29.48   Max: 62.22
Current: 44.8

During the past 12 years, the highest Price-to-Owner-Earnings of Getein Biotech was 62.22. The lowest was 11.21. And the median was 29.48.


SHSE:603387's Price-to-Owner-Earnings is ranked worse than
63.35% of 281 companies
in the Medical Devices & Instruments industry
Industry Median: 33.35 vs SHSE:603387: 44.80

As of today (2024-05-27), Getein Biotech's share price is ¥8.96. Getein Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.48. Therefore, Getein Biotech's PE Ratio for today is 18.67.

As of today (2024-05-27), Getein Biotech's share price is ¥8.96. Getein Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was ¥0.53. Therefore, Getein Biotech's PE Ratio without NRI for today is 16.94.

During the past 12 years, Getein Biotech's highest PE Ratio without NRI was 47.09. The lowest was 9.11. And the median was 21.73.


Getein Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Getein Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech Price-to-Owner-Earnings Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.86 38.30 24.04 16.19 39.86

Getein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.53 31.59 46.32 39.86 46.00

Competitive Comparison of Getein Biotech's Price-to-Owner-Earnings

For the Medical Devices subindustry, Getein Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Getein Biotech's Price-to-Owner-Earnings falls into.



Getein Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Getein Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=8.96/0.20
=44.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getein Biotech  (SHSE:603387) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Getein Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Getein Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Getein Biotech (SHSE:603387) Business Description

Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech (SHSE:603387) Headlines

No Headlines